Medicine and Health

Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

A. Gharbaran, C. C. E. Jordans, et al.

In a randomized clinical trial of 86 hospitalized COVID-19 patients, treatment with convalescent plasma showed no overall clinical benefit despite its safety. The study, conducted by a team of researchers including Arvind Gharbaran and Carlijn C. E. Jordans, highlights that most patients had strong neutralizing antibodies at admission, prompting a shift in focus for future studies towards earlier disease stages.

00:00

Playback language: English

Index

Abstract

A randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care to treatment with 300ml convalescent plasma containing high titers of neutralizing SARS-CoV-2 antibodies showed no overall clinical benefit. A comprehensive translational approach investigated virological and immunological responses to determine which patients might benefit. Convalescent plasma was safe but did not improve survival, disease course, viral clearance, antibody development, or inflammatory cytokine levels. Most patients already had potent neutralizing antibodies at admission, comparable to plasma donors, leading to early trial termination. Future studies should focus on early disease stages or before autologous humoral response.

Publisher

Nature Communications

Published On

May 27, 2021

Authors

Arvind Gharbaran, Carlijn C. E. Jordans, Corine GeurtsvanKessel, Jan G. den Hollander, Faiz Karim, Femke P. N. Mollema, Janneke E. Stalenhoef – Schukken, Anthonuis Dofferhoff, Inge Ludwig, Adrianus Koster, Robert-Jan Hassing, Jeannet C. Bos, Geert R. van Pottelberge, Imro N. Vlasveld, Heidi S. M. Ammerlaan, Elena M. van Leeuwen – Segrecanul, Jelle Miedema, Menno van der Eerden, Thijs J. Schrama, Grigorios Papageorgiou, Peter te Boekhorst, Francis H. Swaneveld, Yvonne M. Mueller, Marco W. J. Schreurs, Jeroen J. A. van Kampen, Barry Rockx, Nisreen M. A. Okba, Peter D. Katsikis, Marion P. G. Koopmans, Bart L. Haagmans, Casper Rokx, Bart J. A. Rijnders

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection

Y. Guo, G. Zhang, et al.

Medicine and Health

Risk factors for and pregnancy outcomes after SARS-CoV-2 in pregnancy according to disease severity: A nationwide cohort study with validation of the SARS-CoV-2 diagnosis of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)

A. J. M. Aabakke, T. G. Petersen, et al.

Biology

Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications

E. C. Abebe and T. A. Dejenie

Medicine and Health

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralizing antibodies in COVID-19 patients

C. M. Poh, G. Carissimo, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny